Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.

Recruiting now

Conditions studied: Prostate Cancer, Metastasis

In brief

Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.

Key facts

Study ID

NCT06700057

Run by

Institut Bergonié

People needed

50

Starts

2023-11-01

Expected to finish

2027-12-31

Last updated by the study team

2026-01-30

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patient aged 18 and over.
• Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01/11/2023:
• Progressive, metastatic, castration-resistant prostate cancer,
• overexpressing prostate specific membrane antigen (PSMA)
• treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone).
• Patient able to lie still for 1 hour for image acquisition.
• Patient's place of residence < 2 hours' drive from the Institut Bergonié.
• Patient has not expressed any opposition to the use of his/her medical data for research purposes.

You may not qualify if…

• None

Where it is running

• Institut Bergonie — Bordeaux, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.